PMID- 11549573
OWN - NLM
STAT- MEDLINE
DCOM- 20011011
LR  - 20240405
IS  - 0002-9440 (Print)
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Linking)
VI  - 159
IP  - 3
DP  - 2001 Sep
TI  - Human leukocyte antigen G up-regulation in lung cancer associates with high-grade 
      histology, human leukocyte antigen class I loss and interleukin-10 production.
PG  - 817-24
AB  - Immune evasion in lung cancer results from both structural and functional 
      alterations of human leukocyte antigen (HLA) class I molecules and the local 
      release of immunosuppressive cytokines. Recent data suggest that HLA-G, a 
      nonclassical class Ib molecule, is involved in immune evasion by tumor cells. We 
      sought to determine whether HLA-G could contribute to immunescape in lung cancer. 
      All of 19 tumor specimens examined demonstrated detectable membrane-bound 
      (HLA-G1), as well as soluble (HLA-G5) isoform transcription. Nine of 34 (26%) 
      tumors were positive by immunohistochemistry using monoclonal antibody (mAb) 
      4H84, recognizing all denatured HLA-G isoforms, of which six were positive using 
      mAb 16G1, recognizing soluble HLA-G. HLA-G immunoreactivity correlated with 
      high-grade histology, with HLA-G being preferentially expressed on large-cell 
      carcinomas. In these patients, loss of classical HLA class I molecules was 
      observed to associate with HLA-G protein up-regulation. Moreover, we found 
      interleukin-10 expressed in 15 of 34 (44%) tumors, and in most of the 
      HLA-G-positive cases (7 of 9), suggesting up-modulation of HLA-G by 
      interleukin-10. It is conceivable that HLA-G expression in lung cancer might be 
      one of the ways how the tumor down-regulates host immune response, in addition to 
      interleukin-10 production and HLA class I loss.
FAU - Urosevic, M
AU  - Urosevic M
AD  - Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
FAU - Kurrer, M O
AU  - Kurrer MO
FAU - Kamarashev, J
AU  - Kamarashev J
FAU - Mueller, B
AU  - Mueller B
FAU - Weder, W
AU  - Weder W
FAU - Burg, G
AU  - Burg G
FAU - Stahel, R A
AU  - Stahel RA
FAU - Dummer, R
AU  - Dummer R
FAU - Trojan, A
AU  - Trojan A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Protein Isoforms)
RN  - 0 (RNA, Messenger)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Aged
MH  - Female
MH  - HLA Antigens/genetics/*metabolism
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/genetics/*metabolism
MH  - Humans
MH  - Interleukin-10/*biosynthesis
MH  - Killer Cells, Natural/pathology
MH  - Lung/metabolism
MH  - Lung Neoplasms/*metabolism/*pathology
MH  - Lymphocytes, Tumor-Infiltrating/pathology
MH  - Male
MH  - Middle Aged
MH  - Protein Isoforms/genetics
MH  - RNA, Messenger/metabolism
MH  - Tumor Cells, Cultured
MH  - Up-Regulation
PMC - PMC1850480
EDAT- 2001/09/11 10:00
MHDA- 2001/10/12 10:01
PMCR- 2002/03/01
CRDT- 2001/09/11 10:00
PHST- 2001/09/11 10:00 [pubmed]
PHST- 2001/10/12 10:01 [medline]
PHST- 2001/09/11 10:00 [entrez]
PHST- 2002/03/01 00:00 [pmc-release]
AID - S0002-9440(10)61756-7 [pii]
AID - 2788 [pii]
AID - 10.1016/S0002-9440(10)61756-7 [doi]
PST - ppublish
SO  - Am J Pathol. 2001 Sep;159(3):817-24. doi: 10.1016/S0002-9440(10)61756-7.